Anti-CD38-Based Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma

(MedPage Today)-Daratoomab (Darzalx) in addition to the standard trio of Puertozomib (Felkadi), Lynalidide (Revlefide), and Dexamethasone (D-VRD) greatly improved clinical results against VRD alone in patients with independence or …